Poseida Therapeutics Leadership

Dr. Ostertag is founder and CEO of Poseida Therapeutics, Inc. (Poseida) and has over 12 years of executive management experience. He has received scientific and clinical awards from the American Society of Human Genetics and the American Society for Apheresis. He completed his undergraduate training at the University of Wisconsin where he received a B.S. in Genetics with Honors. He went on to do both M.D. and Ph.D. (Molecular Biology) degrees at the University of Pennsylvania (UPenn). He later completed a residency program in Clinical Pathology and a Fellowship in Transfusion Medicine at the Hospital of the University of Pennsylvania. He was co-founder and CEO of PhenoTech, Vindico, and later, the founder and CEO of Transposagen and co-inventor of its technologies, publishing nearly twenty peer-reviewed articles and reviews in the field of mobile DNA.

Poseida is a private biotechnology company spun out of Transposagen Biopharmaceuticals, Inc. (Transposagen), and headquartered in San Diego, CA. Poseida is a therapeutics-focused biotechnology company using best-in-class gene editing technologies to develop novel, life-saving therapies, including gene therapy for orphan liver diseases and immuno-oncology therapeutics for several types of cancer. Poseida owns several industry-leading gene editing technologies, including the piggyBac(TM) DNA Modification System, XTN(TM) TALEN and NextGEN(TM) CRISPR site-specific nucleases, and Footprint-Free(TM) Gene Editing (FFGE). FFGE is the cleanest gene editing technology that is commercially available, allowing for surgically-precise changes of as little as a single nucleotide in any genome without unwanted mutations and with the ability to select for otherwise rare events.

Mark Gergen joined Poseida in February 2018 as chief business officer and chief financial officer. Mr. Gergen was previously the senior vice president and chief operating officer of Halozyme, Inc. and executive vice president and chief operating officer at Mirati Therapeutics, Inc. Mr. Gergen served in senior management positions, including as senior vice president of corporate development, at Amylin Pharmaceuticals, Inc. Mr. Gergen served in senior management positions at CardioNet Inc., Advanced Tissue Sciences, Inc. and Medtronic, Inc. Mr. Gergen received a J.D. from the University of Minnesota Law School and a B.A. in business administration from Minot State University.

Highly experienced General Counsel and Senior Business Executive with a demonstrated history of working in the biotechnology, pharmaceutical and medical device industries. Strong legal professional skilled in Corporate Law, Litigation, Biotechnology, Intellectual Property, Corporate Governance, Licensing and Mergers & Acquisitions.

Kristin Martin joined Poseida Therapeutics as chief human resources officer in 2019 where she is providing human resources and business leadership to the fast-growing company. Prior to joining Poseida, Ms. Martin spent five years at Ardea Biosciences, Inc. where she was vice president of human resources, facilities and IT. During her time at Ardea, Ms. Martin helped lead the organization through two successful drug approvals. Ms. Martin has 24 years of human resources experience across multiple industries. The majority of her career has been focused in the life sciences industry working with research and development as well as commercial operations and pharmaceutical manufacturing at Amylin Pharmaceuticals and Vantiv. Ms. Martin received her bachelor’s degree from Bowling Green State University in Ohio.

Dr. Ostertag is founder and CEO of Poseida Therapeutics, Inc. (Poseida) and has over 12 years of executive management experience. He has received scientific and clinical awards from the American Society of Human Genetics and the American Society for Apheresis. He completed his undergraduate training at the University of Wisconsin where he received a B.S. in Genetics with Honors. He went on to do both M.D. and Ph.D. (Molecular Biology) degrees at the University of Pennsylvania (UPenn). He later completed a residency program in Clinical Pathology and a Fellowship in Transfusion Medicine at the Hospital of the University of Pennsylvania. He was co-founder and CEO of PhenoTech, Vindico, and later, the founder and CEO of Transposagen and co-inventor of its technologies, publishing nearly twenty peer-reviewed articles and reviews in the field of mobile DNA.

Poseida is a private biotechnology company spun out of Transposagen Biopharmaceuticals, Inc. (Transposagen), and headquartered in San Diego, CA. Poseida is a therapeutics-focused biotechnology company using best-in-class gene editing technologies to develop novel, life-saving therapies, including gene therapy for orphan liver diseases and immuno-oncology therapeutics for several types of cancer. Poseida owns several industry-leading gene editing technologies, including the piggyBac(TM) DNA Modification System, XTN(TM) TALEN and NextGEN(TM) CRISPR site-specific nucleases, and Footprint-Free(TM) Gene Editing (FFGE). FFGE is the cleanest gene editing technology that is commercially available, allowing for surgically-precise changes of as little as a single nucleotide in any genome without unwanted mutations and with the ability to select for otherwise rare events.

Dr. Ostertag is founder and CEO of Poseida Therapeutics, Inc. (Poseida) and has over 12 years of executive management experience. He has received scientific and clinical awards from the American Society of Human Genetics and the American Society for Apheresis. He completed his undergraduate training at the University of Wisconsin where he received a B.S. in Genetics with Honors. He went on to do both M.D. and Ph.D. (Molecular Biology) degrees at the University of Pennsylvania (UPenn). He later completed a residency program in Clinical Pathology and a Fellowship in Transfusion Medicine at the Hospital of the University of Pennsylvania. He was co-founder and CEO of PhenoTech, Vindico, and later, the founder and CEO of Transposagen and co-inventor of its technologies, publishing nearly twenty peer-reviewed articles and reviews in the field of mobile DNA.

Poseida is a private biotechnology company spun out of Transposagen Biopharmaceuticals, Inc. (Transposagen), and headquartered in San Diego, CA. Poseida is a therapeutics-focused biotechnology company using best-in-class gene editing technologies to develop novel, life-saving therapies, including gene therapy for orphan liver diseases and immuno-oncology therapeutics for several types of cancer. Poseida owns several industry-leading gene editing technologies, including the piggyBac(TM) DNA Modification System, XTN(TM) TALEN and NextGEN(TM) CRISPR site-specific nucleases, and Footprint-Free(TM) Gene Editing (FFGE). FFGE is the cleanest gene editing technology that is commercially available, allowing for surgically-precise changes of as little as a single nucleotide in any genome without unwanted mutations and with the ability to select for otherwise rare events.

Mark Gergen joined Poseida in February 2018 as chief business officer and chief financial officer. Mr. Gergen was previously the senior vice president and chief operating officer of Halozyme, Inc. and executive vice president and chief operating officer at Mirati Therapeutics, Inc. Mr. Gergen served in senior management positions, including as senior vice president of corporate development, at Amylin Pharmaceuticals, Inc. Mr. Gergen served in senior management positions at CardioNet Inc., Advanced Tissue Sciences, Inc. and Medtronic, Inc. Mr. Gergen received a J.D. from the University of Minnesota Law School and a B.A. in business administration from Minot State University.